EUCTR2004-001617-34-IT进行中（未招募）不适用
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATIO
FUJISAWA0 个研究点开始时间: 2005年6月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATION - Marsilea (Mycophenolate mofetil or Antibodies with Reduced Steroids in Liver transplantation)Patients with hepatic disease who will undergo primary orthotopic liver or split liver allograft transplantation.MedDRA version: 7.0Level: LLTClassification code 10019650EUCTR2004-001617-34-GBAstellas Pharma Europe Ltd600
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATION - Marsilea (Mycophenolate mofetil or Antibodies with Reduced Steroids in Liver transplantation)Patients with hepatic disease who will undergo primary orthotopic liver or split liver allograft transplantation.MedDRA version: 7.0Level: LLTClassification code 10019650EUCTR2004-001617-34-SEAstellas Pharma Europe Ltd600
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATION - Marsilea (Mycophenolate mofetil or Antibodies with Reduced Steroids in Liver transplantation)Patients with hepatic disease who will undergo primary orthotopic liver or split liver allograft transplantation.MedDRA version: 7.0Level: LLTClassification code 10019650EUCTR2004-001617-34-HUAstellas Pharma GmbH600
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATION - Marsilea (Mycophenolate mofetil or Antibodies with Reduced Steroids in Liver transplantation)Patients with hepatic disease who will undergo primary orthotopic liver or split liver allograft transplantation.MedDRA version: 7.0Level: LLTClassification code 10019650EUCTR2004-001617-34-DKAstellas Pharma GmbH600
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATION - Marsilea (Mycophenolate mofetil or Antibodies with Reduced Steroids in Liver transplantation)EUCTR2004-001617-34-BEFujisawa GmbH600